Though intravitreal anti-VEGF is by far the most frequently used therapy to treat PDR and DME, it has been shown that DME patients often have a less robust response to anti-VEGF therapy compared to patients treated for neovascular age-related macular degeneration or retinal vein occlusion [9]. The gene discussed is VEGFA; the disease is wet macular degeneration.